GEMVAX Participates as Main Sponsor of 'Neuro 2024'

GemVax & Kael announced on the 28th that it will participate as the main sponsor of the international research symposium on progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), 'Neuro2024.'

'Neuro2024' is an annual academic conference hosted by CurePSP, where experts in the field of neuroscience from around the world gather to share various research findings on PSP and CBD. This year, it will be held in Toronto, Canada, over two days from October 24 to 25.

Founded in 1990, CurePSP is a nonprofit charitable organization based in New York, USA. It provides extensive support through a broad network of experts, patients, and patient families by raising awareness of PSP, CBD, and multiple system atrophy (MSA), building communities, and supporting innovative research on causes and treatments.

GemVax will share preclinical research results of GV1001, the status of domestic clinical trials, and plans for global clinical trials, strengthening its global network with prominent researchers and patient organizations in the neuroscience field.

GemVax is conducting the first PSP clinical trial in Korea and is preparing for global clinical trials. The domestic Phase 2 clinical trial is expected to complete dosing for all patients by September, with clinical results anticipated by the end of this year or early next year. Earlier this year, it was designated as a 'Developmental Stage Orphan Drug' by the Ministry of Food and Drug Safety.

The PSP clinical trial is currently being prepared after receiving approval for the Phase 2 clinical trial plan from the U.S. Food and Drug Administration (FDA) in February, with plans to apply for approval from the UK and European Medicines Agency (EMA) in the future.

A GemVax representative introduced CurePSP as "a nonprofit organization that firmly establishes a global network of PSP patients, their families, and experts, leading efforts to improve awareness of the disease as well as treatment, education, and quality of life." They added, "We will continue to develop various cooperation plans with CurePSP and strive to strengthen networks for the smooth progress of global clinical trials."

PSP is an atypical Parkinsonian syndrome and the most severe form among Parkinsonian disorders. Its main symptoms include gait disturbance, postural instability, cognitive decline, ocular motor dysfunction, and sleep disorders. The disease progresses rapidly, and no fundamental treatment has yet been developed.